Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
NextPoint Therapeutics, Inc.
Guangzhou Women and Children's Medical Center
Clovis Oncology, Inc.
Xuanwu Hospital, Beijing
Brazilian National Cancer Institute